Table 5.

Summary of human in vivo F _g values estimated by indirect or PBPK approaches and from literature

		Human in vivo F g (PBPK or indirect approaches)	F g (Karlsson) 12	F g (Gertz) 15	F g (Yang) 14	F g (Gertz) 57
1	Alprazolam	0.91	0.94	0.94	0.86	0.89*
2	Alprenolol	1
3	Chlorpromazine	0.38
4	Clozapine	0.31
5	Cyclosporine	0.82	0.6	0.44	0.62*	0.65*
6	Diltiazem	0.94
7	Domperidone	0.45
8	Erythromycin	0.30	0.23
9	Felodipine	0.65	0.38	0.45	0.58*	0.53*
10	Flumazenil	1
11	Itraconazole	0.72
12	Lidocaine	0.82
13	Metoprolol	1
14	Midazolam	0.69	0.52	0.51	0.57**	0.57*
15	Mirtazapine	1
16	Nalbuphine	1
17	Nicardipine	0.78
18	Nifedipine	0.87	0.47	0.74	0.68*	0.62*
19	Nimodipine	0.22
20	Nisoldipine	0.15		0.11
21	Nitrendipine	0.58
22	Omeprazole	1
23	Saquinavir	0.12	0.47	0.18	0.67*	0.54*
24	Sildenafil	0.83	0.7	0.54		0.82*
25	Tacrolimus	0.39	0.36	0.14	0.26
26	Tolterodine	0.60
27	Triazolam	0.64	0.63	0.75	0.67*	0.4*
28	Venlafaxine	1
29	Verapamil	0.51	0.4	0.65		0.71*
30	Zolmitriptan	0.54
31	Zolpidem	0.92		0.79

^* Determined from an interaction study using grapefruit juice as enzyme inhibitor.

^** Determined in anhepatic patients after intraduodenal drug administration.